IL6 and metabolic dysfunction-associated steatohepatitis: Significant decreases in plasma levels of VEGF, FGF, PDGF, liver tumor necrosis factor (TNFα), IL-1b, IL-6, and IL-17 were observed in NASH-cirrhotic plus brivanib and NASH-cirrhotic plus sorafenib rats during the treatment period if compared to those treated with vehicle alone [48].